B
Bianca Lederer
Researcher at Goethe University Frankfurt
Publications - 35
Citations - 2381
Bianca Lederer is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Breast cancer & Neoadjuvant therapy. The author has an hindex of 15, co-authored 33 publications receiving 1521 citations.
Papers
More filters
Journal ArticleDOI
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert,Gunter von Minckwitz,Silvia Darb-Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang D. Schmitt,Jens-Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiss,Arndt Hartmann,Aurelia Noske,Peter A. Fasching,Christian Jackisch,Marion van Mackelenbergh,Peter Sinn,Christian Schem,Claus Hanusch,Michael Untch,Sibylle Loibl +26 more
TL;DR: The hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies is supported and increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed.
Journal ArticleDOI
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen,Bianca Lederer,Jan Hauke,Sibylle Loibl,Sandra Kröber,Andreas Schneeweiss,Carsten Denkert,Peter A. Fasching,Peter A. Fasching,Jens Uwe Blohmer,Christian Jackisch,Stefan Paepke,Bernd Gerber,Sherko Kümmel,Christian Schem,Guido Neidhardt,Jens Huober,Kerstin Rhiem,SD Costa,Janine Altmüller,Claus Hanusch,Holger Thiele,Volkmar Müller,Peter Nürnberg,Thomas Karn,Valentina Nekljudova,Michael Untch,Gunter von Minckwitz,Rita K. Schmutzler +28 more
TL;DR: Evidence is provided that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).
Journal ArticleDOI
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner,Michael Untch,Carsten Denkert,Berit M. Pfitzner,Bianca Lederer,Wolfgang D. Schmitt,Holger Eidtmann,Peter A. Fasching,Hans Tesch,Christine Solbach,Mahdi Rezai,Dirk Michael Zahm,Frank Holms,Manfred Glados,Petra Krabisch,Esther Heck,Angelika Ober,Petra Lorenz,Kurt Diebold,Jörg-Olaf Habeck,Sibylle Loibl +20 more
TL;DR: In combination with pCR rate, TILs may help to stratify prognostic subgroups, thereby guiding future therapy decisions and demonstrating the predictive and prognostic impact of Tils in HER2-positive breast cancer in the neoadjuvant setting.
Journal ArticleDOI
Standardized Ki67 diagnostics using automated scoring - clinical validation in the GeparTrio breast cancer study
Frederick Klauschen,Stephan Wienert,Wolfgang D. Schmitt,Sibylle Loibl,Bernd Gerber,Jens-Uwe Blohmer,Jens Huober,Thomas Rüdiger,Erhard Erbstößer,Keyur Mehta,Bianca Lederer,Manfred Dietel,Carsten Denkert,Gunter von Minckwitz +13 more
TL;DR: The computer-assisted Ki67 scoring approach presented here offers a standardized means of tumor cell proliferation assessment in breast cancer that correlated with clinical endpoints and is deployable in routine diagnostics.
Journal ArticleDOI
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Caterina Fontanella,Bianca Lederer,Stephan Gade,Mieke Vanoppen,Jens Uwe Blohmer,Serban-Dan Costa,Carsten Denkert,Holger Eidtmann,Bernd Gerber,Claus Hanusch,Jörn Hilfrich,Jens Huober,Andreas Schneeweiss,Stefan Paepke,Christian Jackisch,Keyur Mehta,Valentina Nekljudova,Michael Untch,Patrick Neven,Gunter von Minckwitz,Sibylle Loibl +20 more
TL;DR: Normal weight patients had the best compliance to chemotherapy and received the highest taxane doses, which seems to be related with treatment outcomes, according to BC subtypes in patients with primary BC treated with neoadjuvant chemotherapy.